Back to Search Start Over

Abstract LB-330: Genetic variants in the 9p21 region in relation to the risk of multiple tumors

Authors :
Rose Yang
Alisa M. Goldstein
Ruth M. Pfeiffer
Christian C. Abnet
Jorge R. Toro
Summer S. Han
Christian P. Kratz
Jolanta Lissowska
Alice J. Sigurdson
Margaret A. Tucker
Ti Ding
Phil R. Taylor
Alina V. Brenner
Fangyi Gu
Sanford M. Dawsey
Nicolas Wentzensen
Montserrat Garcia-Closas
Lee E. Moore
Laurie Burdette
Meredith Yeager
You-Lin Qiao
Sharon A. Savage
Wong-Ho Chow
Sonja I. Berndt
Stephen J. Chanock
Nan Hu
Regina G. Ziegler
Lisa Mirabello
Hanna Yang
Neal D. Freedman
Louise A. Brinton
Source :
Cancer Research. 72:LB-330
Publication Year :
2012
Publisher :
American Association for Cancer Research (AACR), 2012.

Abstract

Chromosome 9p21 has been implicated in the pathogenesis of cutaneous malignant melanoma (CMM), glioma, non-small cell lung cancer, and leukemia. This region includes cyclin-dependent kinase inhibitor 2A (CDKN2A), the major known high-risk susceptibility gene for CMM; CDKN2B; antisense noncoding RNA in the INK4 locus (ANRIL), a GWAS hotspot for multiple phenotypes including cancers; methylthioadenosine phosphorylase (MTAP), a gene with tumor suppressor function and a cluster of type I interferon (IFN) genes. The goal of this study was to examine the association between genetic variation in the 9p21 region and multiple cancer outcomes using genotyping data from studies participating in the National Cancer Institute's (NCI) iSelect project. We evaluated up to 202 tagSNPs in 22 genes in the 9p21 region (19.9-32.8 Mb), in case-control studies of thyroid cancer (THC), endometrial cancer (EC), testicular cancer (TC), renal cell carcinoma (RCC), colorectal cancer (CRC), colorectal adenoma (CA), esophageal squamous cell carcinoma (ESCC), gastric cardia cancer (GCC) and osteosarcoma (OS). The number of cases in each of the nine studies ranged from 96 to 1234. We first performed single SNP-based analyses for each study separately, using logistic regression adjusted for age and study-specific covariates. To combine SNP based analyses, we used a newly developed subset-based statistical approach (ASSET), which allow for heterogeneity of SNP effect on different outcomes. This approach exhaustively explores subsets of studies for the presence of association signals, and then evaluates the significance from subsets with the strongest association signal, meanwhile accounting for multiple tests required by the subset search. Gene based P-values were computed using an adaptive rank truncated product (ARTP) statistic and a permutation-based sampling procedure (10,000 permutations) that took into account the numbers of SNPs in each gene and their linkage disequilibrium structure. When analyzing each study separately, we found that a SNP (rs3731257) in CDKN2A was significantly associated with the risk of ESCC after Bonferroni correction for number of SNPs and studies (P=7 x 10-6). Meta-analyses by ASSET found that this SNP was significantly associated with both ESCC and EC (PASSET Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-330. doi:1538-7445.AM2012-LB-330

Details

ISSN :
15387445 and 00085472
Volume :
72
Database :
OpenAIRE
Journal :
Cancer Research
Accession number :
edsair.doi...........809decf890c50f26cadaefb995ffbf29